Granzyme B nanoreporter for early monitoring of tumor response to immunotherapy

Novel patterns of response under immunotherapy

(2019) E Borcoman et al.   ANNALS OF ONCOLOGY

Tumor targeting via EPR: Strategies to enhance patient responses

(2018) Susanne K. Golombek et al.   ADVANCED DRUG DELIVERY REVIEWS

Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies

(2018) Roberta Zappasodi et al.   CANCER CELL

Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression

(2018) Heng Lin et al.   JOURNAL OF CLINICAL INVESTIGATION

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

(2018) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion

(2018) Flávia Castro et al.   Frontiers in Immunology

PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity

(2017) Vikram R. Juneja et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells

(2017) Mohammad Rashidian et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma

(2017) Khun Visith Keu et al.   Science Translational Medicine

Modulation of let-7 miRNAs controls the differentiation of effector CD8 T cells

(2017) Alexandria C Wells et al.   eLife

Modulating the Tumor Microenvironment to Enhance Tumor Nanomedicine Delivery

(2017) Bo Zhang et al.   Frontiers in Pharmacology

Reporter nanoparticle that monitors its anticancer efficacy in real time

(2016) Ashish Kulkarni et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy

(2015) R. Tavare et al.   CANCER RESEARCH

How Do Cytotoxic Lymphocytes Kill Cancer Cells?

(2015) L. Martinez-Lostao et al.   CLINICAL CANCER RESEARCH

Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future

(2015) Lieping Chen et al.   JOURNAL OF CLINICAL INVESTIGATION

Pseudoprogression and Immune-Related Response in Solid Tumors

(2015) Victoria L. Chiou et al.   JOURNAL OF CLINICAL ONCOLOGY

Principles of nanoparticle design for overcoming biological barriers to drug delivery

(2015) Elvin Blanco et al.   NATURE BIOTECHNOLOGY

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Noninvasive imaging of immune responses

(2015) Mohammad Rashidian et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Oncogene Pathway Activation in Mammary Tumors Dictates FDG-PET Uptake

(2014) J. V. Alvarez et al.   CANCER RESEARCH

Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study

(2014) Christos Sachpekidis et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

(2014) Thomas Powles et al.   NATURE

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements

(2013) M. Nishino et al.   CLINICAL CANCER RESEARCH

Immune Monitoring in Cancer Vaccine Clinical Trials: Critical Issues of Functional Flow Cytometry-Based Assays

(2013) Iole Macchia et al.   Biomed Research International

Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity

(2012) P. Sengupta et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Theranostic Nanomedicine

(2011) Twan Lammers et al.   ACCOUNTS OF CHEMICAL RESEARCH

T-Cell Immune Function in Tumor, Skin, and Peripheral Blood of Advanced Stage Melanoma Patients: Implications for Immunotherapy

(2011) E. P. M. Tjin et al.   CLINICAL CANCER RESEARCH

Theranostic nanoplatforms for simultaneous cancer imaging and therapy: current approaches and future perspectives

(2011) Ki Young Choi et al.   Nanoscale

Cancer immunotherapy comes of age

(2011) Ira Mellman et al.   NATURE

Tumor-homing multifunctional nanoparticles for cancer theragnosis: Simultaneous diagnosis, drug delivery, and therapeutic monitoring

(2010) Kwangmeyung Kim et al.   JOURNAL OF CONTROLLED RELEASE

Conscripts of the infinite armada: systemic cancer therapy using nanomaterials

(2010) David A. Scheinberg et al.   Nature Reviews Clinical Oncology

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH